Several prominent public health incidents [29] that occurred at the beginning of this century due to adverse drug events (ADEs) have raised international awareness of governments and industries about pharmacovigilance (PhV) [6, 7] , the science and activities to monitor and prevent adverse events caused by pharmaceutical products a er they are introduced to the market. A major data source for PhV is large-scale longitudinal observational databases (LODs) [6] such as electronic health records (EHRs) and medical insurance claim databases. Inspired by the Multiple Self-Controlled Case Series (MSCCS) model [27] , arguably the leading method for ADE discovery from LODs, we propose baseline regularization, a regularized generalized linear model that leverages the diverse health pro les available in LODs across di erent individuals at di erent times. We apply the proposed method as well as MSCCS to the Marsh eld Clinic EHR. Experimental results suggest that incorporating the heterogeneity among di erent patients and di erent times help to improve the performance in identifying benchmark ADEs from the Observational Medical Outcomes Partnership ground truth [26] .
INTRODUCTION
Pharmacovigilance (PhV) [6, 7] is the science and activities relating to the surveillance and prevention of adverse events caused by pharmaceutical products a er they are introduced to the market. In response to several recent prominent public health hazards [29] due to adverse drug events (ADEs), governments, industries, and other stakeholders across the world have been building e ective PhV systems to safeguard admissible pro t-risk pro les of drug products on the market.
Major PhV systems [3, 8, 20] nowadays leverage a network of large-scale longitudinal observational databases (LODs) [6] such as electronic health records (EHRs) and medical insurance claim databases that contain individual-level time-stamped rich medical data collected globally from hundreds of millions of individuals. All the databases within the network are updated periodically and are converted to the same format; various ADE discovery algorithms can hence be run regularly on di erent databases without any modi cations to achieve proactive drug safety surveillance.
An e cient algorithm that can deliver accurate ADE identi cation using LODs is hence of utmost importance to the performance of PhV systems. A leading algorithm is the Multiple Self-Controlled Case Series (MSCCS) method [27] . Using the occurrence of a condition of interest from di erent patients at di erent times as the response variable, and the corresponding exposure statuses of various drugs as the features, MSCCS is a parsimonious representation of a xed e ect Poisson regression model [34] . In MSCCS, each patient acts as his or her own control, during exposed (case) or unexposed (control) periods of time, thus controlling even for latent and unconsidered factors, provided they are time-invariant.
However, due to the longitudinal nature of the data, simply adjusting for time-invariant confounding does not su ce to deliver accurate modeling. For example, the occurrence rate of adverse events such as heart a acks usually increases as the observed individual ages. Moreover, patients that previously had heart a acks will also be prone to have another one in the future. Neither of the aforementioned time-varying occurrence rates of heart a ack can be modeled by adjusting for time-invariant confounding via MSCCS.
By assuming an individual-speci c, time-dependent occurrence rate of adverse events, the mission of the proposed Baseline Regularization (BR) method is to provide exibility to model the temporal nature of LODs, in the hope of delivering more e ective ADE discovery. Our contributions are three-fold:
• BR is the rst general-purpose ADE discovery algorithm following a self-controlled design that exploits the time-varying perspective of individual pro les in large-scale LODs.
• BR is deeply connected to and is a generalization of some of the existing models in the literature. BR not only directly generalizes MSCCS, it is also a generalized linear model that extends [10] , which deals with baseline regularization in a linear model se ing.
• Experimental results suggest that incorporating the heterogeneity among di erent patients and di erent times help to improve the performance in identifying benchmark ADEs from the Observational Medical Outcomes Partnership ground truth [26] .
2 MODEL SPECIFICATION 2.1 Background Figure 1 visualizes the EHR from a patient that has taken two drugs and has had four heart a acks throughout his 400 days of observation. e rectangular bands in di erent colors represent di erent drug eras, each representing a consecutive time period during which the patient was exposed to a particular drug. A drug era is recorded with its start date, end date, and the name of the drug. e black arrows pointing downwards annotated with MI (Myocardial Infarction) represent the date on which the patient had a heart a ack. e gray dashed lines and the indices on the top of the gure represent di erent intervals, a concept that we will de ne later in Section 2.3. In this paper, we consider the multiple-drug, single-ADE se ing. As an illustrative example, our task of using the EHR from the patient presented in Figure 1 and from many other patients is to determine whether the exposure to certain drugs might cause the occurrence of MI as an adverse event.
Suppose there are M drugs and N patients in the EHR database. We use i to represent the total number of days of observation available in the EHR of patient i, where i ∈ {1, 2, · · · , N }. We use χ i jm to represent a binary drug exposure status of drug m on the j t h day during the observation of the i t h patient, where j ∈ {1, 2, · · · , i }, and m ∈ {1, 2, · · · , M }. χ i jm = 1 represents exposure and χ i jm = 0 represents non-exposure. We further use i j to represent a binary MI occurrence variable with i j = 1 meaning that the i t h patient has an MI on the j th day during the observation, and i j = 0 otherwise. With the notation introduced above, we can consider i j 's as a response variable and χ i jm 's as features. Following the convention of MSCCS, we will use a Poisson regression model (instead of a logistic regression model even though the response is binary) to depict the relationship between the response variable and the features, resulting in the following log-likelihood function:
where
e occurrence rate of MI to the i t h patient on the j t h day during observation is hence given by exp τ i j + χ i j β , from which we can infer that the rate is determined by two contributing factors. e rst one depends on the joint drug exposure statuses, described by χ i j , and the e ect of each drug on the occurrence rate of MI, given by β. If the value of a particular component of β is especially large, then the occurrence rate of MI will increase upon the exposure of the corresponding drug. erefore, such a drug might potentially cause MI as an ADE. e second factor is the baseline parameter τ i j , which models the inherent occurrence rate of MI for the i t h patient on day j excluding the interference of the e ects from other covariates modeled by β.
Baseline Regularization
Baseline Parameters e introduction of the baseline parameters τ i j 's in (1) is strikingly simple, and yet it o ers tremendous exibility to portray the heterogeneity of adverse event occurrence rates among di erent patients, and during di erent time periods within the same patient.
For example, a person who has High Blood Pressure (HBP) might have an inherently higher risk for heart a ack compared with a healthy person.
erefore, the baseline parameters for the HBP patients might be higher compared with those of a healthy person. Within the same individual, commonsense-supported observations in the EHRs o en suggest that one should vary baseline parameters temporally: for example, the risk for heart a ack tends to increase in general as a person ages; a patient who has a history of heart a ack might also be more likely to have another heart a ack in the future. In both cases, a set of baseline parameters with increasing tendency along time within the same patient might be introduced to model such observations.
On the other hand, MSCCS makes the following more restrictive modeling assumptions:
at is, MSCCS assumes that baseline parameters can only di er among di erent patients. Within the same patient, baseline parameters do not vary across time. While this modeling assumption is reasonable to address for time-invariant confounding such as gender, socioeconomic status, and genetic pro le, it easily fails to model the aforementioned time-varying occurrence rates.
Regularization
An observant reader might have already noticed that the modeling exibility introduced by baseline parameters τ i j 's in (1) comes with the steep cost of overparameterization: the number of baseline parameters introduced is equal to the sample size of the data! Furthermore, in a typical EHR se ing there could be thousands of drugs available. Modeling the e ects of all these drugs will introduce a β whose dimension is easily on the order of thousands. e high dimensionality of both τ and β motivates us to reduce the degrees of freedom of the model via sparse regularization, which results in the baseline regularization optimization problem as follows:
(2) Here in (2) we use a lasso penalty to regularize β because we assume that among thousands of drugs, there can only be a few that in uence the occurrence rate of MI. We use a fused lasso penalty [9, 19, 31] to regularize τ . e intuition behind using this penalty is that we assume the change between two adjacent baseline parameters is steady and gradual, and hence the baseline occurrence rate should not di er much from one day to another between two days that are adjacent to each other.
We also use a ridge penalty to regularize τ . e necessity for including this penalty can be seen from the observations between day 201 and day 230 in Figure 1 . During this time period (interval I-8), i j = 0, and χ i j = 0, ∀j ∈ {201, 201, · · · , 230}, where for convenience we assume that the patient in Figure 1 is indexed by i.
erefore, during this time period, τ i j 's will tend to be very negative in order to drive the occurrence rate exp(τ i j ) to a number that is very close to zero for a maximum likelihood interpretation of the data. In this scenario, a very negative τ i j might over t the data.
erefore, a ridge penalty that encourages smaller magnitudes of τ i j 's is desirable to avoid over ing. Furthermore, a ridge penalty can also encourage similarity among di erent components of τ , which also helps to foster the assumption that adjacent baseline occurrence rates should not di er much from one another. Using a ridge penalty is a common practice in many other densely parameterized machine learning models, with the most famous and popular example being (deep) neural networks [5, 13] .
Scaling up Baseline Regularization
Even with the regularization introduced in (2), the computational burden of solving the BR model can still be staggeringly heavy.
is is because a typical EHR database can easily contain billions of days of observations from all the patients; each day will require a separate baseline parameter to describe the baseline occurrence rate of an adverse event.
Intervals
To achieve scalability without much loss of modeling exibility, we learn lessons from the idea of data squashing [11, 27] that exploits the discreteness and the sparsity of the data under consideration. Speci cally, within the observational history of a particular patient, we de ne an interval as a consecutive time period during which the drug exposure statuses of all drugs and the cumulative number of adverse event occurrences remain unchanged.
Based on this de nition, Figure 1 visualizes a patient's EHR that is divided into thirteen intervals. Each interval is indexed by I-k on the top of the gure, where k ∈ {1, 2, · · · , 13}. e start date of each interval is passed through by a gray dashed line. erefore, a previous interval ends right before a dashed line. For example, inclusively, I-1 starts from day 1 and ends at day 20 instead of day 21. Similarly, I-2 starts from day 21 and ends at day 60 instead of day 61. An exception for the unchanged cumulative adverse event occurrence restriction upon an interval is allowed if an adverse event occurs at the end of the observation. For example, in Figure 1 , we consider I-13 ranges from day 361 to the end of the observation (day 400) even if on the last day there is a new occurrence of MI.
e reason for allowing such an exception is to avoid a short (one day) interval at the end of an observation.
e concept of an interval provides convenience in describing the data concisely, and hence achieves the goal of data squashing. In Figure 1 , instead of describing the data using information from 400 days, we can now use information from only thirteen intervals.
Parameter Tying
To reduce the number of baseline parameters used for modeling, we tie similar parameters together to the same value. Speci cally, we consider two parameter tying strategies.
• Interval Tying: We can consider that the baseline parameters within the same interval are the same. In this case, within a patient, the number of baseline parameters used is equal to the number of intervals instead of the number of days of observation. In Figure 1 , this parameter tying strategy reduces the number of baseline parameters from 400 to thirteen. • Occurrence Tying: We can even further tie baseline parameters from similar intervals together. For example, since ADEs are usually recurrent, and the baseline risk of ge ing a subsequent ADE usually changes compared with ge ing the rst one, we can tie intervals that have the same cumulative number of adverse event occurrences together. In Figure 1 , this parameter tying strategy will further reduce the number of baseline parameters from thirteen to four, partitioned as:
Reformulation
We now reformulate the BR model in (2) using intervals and parameter tying. Let K i denote the number of intervals that the EHR of the i t h patient is partitioned into. Let κ i represent the number of baseline parameters used in BR a er parameter tying either via interval tying or via occurrence tying. We de ne the vector of baseline parameters a er tying as:
en the baseline parameter for each interval can also be represented as a vector: Zt, where Z is a
design matrix that maps the tied baseline parameters to the baseline parameters for each interval. Note that if the interval tying strategy is adopted, then κ i = K i , and Z = I, where I represents an identity matrix. is is because under the interval tying strategy, each interval will have its own baseline parameter. Furthermore, we use l ik to represent the duration (time length) of the k t h interval from the i th patient, where k ∈ {1, 2, · · · , K i }. And we use n ik to represent the number of adverse event occurrences during the k t h interval of the i th patient. We further use an M × 1 binary vector x ik to represent the drug exposure statuses during the k t h interval of the i th patient. e reason why we need only one exposure vector to represent multiple days within an interval is due to the property of unchanged drug exposure statuses of any one interval. Stacking up l ik 's, n ik 's, and x ik 's results in their vector and matrix representations:
Using Z, t, X, β, l, and n, we can rewrite the log-likelihood function in (1) in a matrix and vector form as follows:
where exp(·) represents a component-wise exponentiation. A er parameter tying, the fused lasso penalties imposed on τ in (2) become fused lasso penalties imposed on the adjacent components of t that are from the same patient because under parameter tying:
We de ne D q and D as follows:
where D q is a (q − 1) × q rst di erence matrix, and D is a blockwise rst di erence matrix. Note that q ∈ N + , and we de ne
With (2), (3), (4), and (5), we can reformulate the BR problem compactly as: (6) where we impose the same strength of ridge regularization using λ 3 on all the components of t.
OPTIMIZATION ALGORITHM
is section provides an optimization algorithm for solving the compact BR model in (6) . Following the idea of glmnet [4] , we adopt an iteratively reweighted least squares (IRLS) approach to quadratically approximate the negative log-likelihood function. Observe that both the negative log-likelihood function and its quadratic approximation are convex, and β and t are separable in the regularization terms; we hence can perform blockwise minimization that alternates between β and t to achieve convergence [32] .
adratic Approximation
At iteration p, the iterates t (p) and β (p) are given. We therefore can perform a quadratic approximation of (3) centered at the current iterates, in order to search for the next iterates that are closest to optimality in the vicinity of the current iterates. Optimizing the quadratic approximation is equivalent to solving a weighted least squares problem as follows:
where the working response is:
with e derivation of the quadratic approximation for (3) basically follows from deriving the quadratic approximation of a standard Poisson regression model and the details are provided in the Appendix.
Blockwise Minimization
With quadratic approximation, at iteration p with the iterates t (p) and β (p) available, the next iterates can be obtained by considering the following optimization problem:
We will adopt a blockwise minimization strategy that xes t and β alternatively and solves for the other until the iterates reach the optimality of (9) . e optimization can hence be formulated as iterating between two steps: a β-step and a t-step.
β-Step
We rst initializet = t (p) . For each β step, we x t =t and solve the subproblem with respect to only β forβ:
which is an L 1 -regularized linear regression problem that can be solved e ciently by existing packages.
t-Step
For each t step, we x β =β, and solve the subproblem with respect to only t fort:
Algorithm 1 Baseline Regularization
Require: Z, X, D, l, n, λ 1 , λ 2 , and λ 3 . Ensure:β andt. Solve forβ via (10) .
Solve fort via (12) . t-Step
9:
if Inner loop stopping criteria met then 10:
p ← p + 1, β (p) ←β, and t (p) ←t.
11:
break.
12:
end if 13: end while
14:
if Outer loop stopping criteria met then
returnβ andt.
17:
end if 18: end while e problem in (11) is equivalent to:
with
e derivation from (11) to (12) is based on algebraic manipulation. Speci cs are presented in the Appendix. e problem in (12) is a blockwise weighted fused lasso signal approximator problem. Ecient linear time algorithms exist for solving this type of problem [1, 2, 9, 19] . Furthermore, from (5) we notice that D is blockwise, so the solutions to di erent blocks are independent of each other. erefore, (12) can be partitioned into various independent subproblems that can be solved in parallel for further speedup.
Implementation
e optimization algorithm for the BR model is summarized in Algorithm 1. Several important implementation details follow:
• To solve the problem in Step 7, we use the glmnet [4] package available in R. To solve the problem in Step 8, we use the functions from the C library of the glmgen [19] package in R. Both implementations are considered to be the state-of-the-art solvers for the respective subproblems.
• To avoid the divergence issue due to an ill-conditioned W (p) , we set all the diagonal elements of W (p) that are smaller than a certain threshold, ϵ, to that threshold. In our experiments, we choose ϵ = 10 −5 . Our compact BR model by design helps to alleviate the ill-conditioned issue because a diagonal element of W (p) represents the cumulative occurrence rate of adverse events during an entire interval. Ridge regularization over baseline parameters also helps to avoid small diagonal elements. • Selection of the inner loop stopping criteria in Step 9 and the outer loop stopping criteria in Step 14 is problem-speci c. We describe our choice in Section 4.4.
Our algorithmic framework shares similarities with that of glmnet. Both methods in the outer loop perform a quadratic approximation to a generalized linear model negative log-likelihood objective with non-smooth regularization. Both methods leverage an e cient inner loop blockwise minimization solver for the approximated problem. erefore, both can be considered being in the family of proximal Newton methods [17, 28] . Compared with rst order methods, it is well known that the proximal Newton method shares the same fast convergence rate as the usual Newton method in terms of the number of (proximal) Newton's steps needed (i.e., the number of outer loop iterations needed). However, proximal Newton methods su er from ine ciency due to the expensive evaluations of the Hessian matrix in general. erefore, the fact that methods under the proximal Newton framework such as glmnet can deliver solutions for even large-scale problems e ciently is counter-intuitive at rst glance, and yet is actually a ainable using an e cient inner solver [17] . Further illustrated by the experimental results to come, our algorithm provides yet another example demonstrating that the proximal Newton framework, with appropriate execution, can have the potential to handle large-scale problems e ectively.
EXPERIMENTS 4.1 e Benchmark Task
To empirically evaluate the performance of our proposed method, we use a ground truth set of 53 drug-condition pairs generated by a selective combination of ten di erent drugs and nine di erent conditions proposed by the Observational Medical Outcomes Partnership (OMOP) [26] , which was a pilot project in the U.S. aiming to conduct methodological research for the identi cation of ADEs from LODs. Among the 53 drug-condition pairs, 9 pairs are identi ed as positive cases (con rmed ADEs), and the remaining 44 are identi ed as negative controls. Distinguishing positive cases from the negative controls in the OMOP ground truth is widely considered to be a benchmark task for ADE discovery from LODs.
Data Source
We use the Marsh eld Clinic EHR database as our data source. Being a pioneer for deploying EHR systems, Marsh eld Clinic EHR database is one of the richest and the most historic in the United States, with coded diagnoses recorded as early as in 1960, and other electronic contents dating back to the 1980s [18] . We convert the diagnosis records and the drug prescription records in the EHRs to a format that is compliant with the vocabularies used in the OMOP ground truth. Following the design of MSCCS, we admit a patient into the cohort if he or she has at least one condition of interest (adverse event) occurrence throughout the entire observation. We also further restrict our a entions to patients with at least one OMOP ground truth drug prescription record during the entire observation. Table 1 provides summary statistics of the cohort used in our experiments.
Cohort Design
We consider two important cohort design choices:
• Risk Window Design: a risk window is a time span that follows right a er the end of a drug era during which the patient is still considered under exposure. ree types of risk windows are considered, none, one month, and lasting. e names of the risk windows are suggestive of their meanings.
• Minimum Duration Design: duration is the time length of the observation for a patient. Other than meeting the cohort admission requirement speci ed in Section 4.2, we admit a patient only when his or her observation duration surpasses the minimum duration threshold. We set three di erent minimum duration thresholds in our experiments, none, three months, and six months.
BR Algorithmic Design Stopping Criteria
We denote the Euclidean norm of the di erence of the two parameter vectors from the last two inner (outer) loop iterations as δ i (δ o ). We denote the number of inner (outer) loop iterations that have run so far as c i (c o ). e design of the inner loop stopping criteria follow a coarseto-ne strategy depending on how close the current outer loop iterate is to optimality. Speci cally, the inner loop stopping criteria are met if any one of the following three conditions is true: (1) δ o > 10 and δ i < 0.05δ o ; (2) δ o ≤ 10 and δ i < max 10 −3 δ o , 10 −4 ; (3) c i ≥ 200. e rst criterion is useful when the current outer loop iterate is far from optimality (characterized by δ o > 10). In this case, a small number of inner loop iterations can decrease the objective e ectively such that δ i < 0.05δ o , but further inner loop iterations do not yield much more progress. erefore, this criterion allows the rst several iterations that make signi cant progress, but truncates the rest that are not as e ective. e second criterion determines when the inner loop stops when the current outer loop iterate is close to optimality (characterized by δ o ≤ 10). In this case, the inner loop estimation needs to be more accurate to ensure that solving subsequent quadratic approximations can further decrease the objective. erefore, the second criterion dictates that the inner loop will stop only when the estimation error is reasonably small. e outer loop stopping criteria are met if either one of the following two conditions is true: (i) c o ≥ 60; (ii) δ o < 10 −4 . Note that a er each outer loop iteration, c i is reset to 0.
Tuning Parameters
Since there are only ten di erent drugs available in the OMOP ground truth, the dimension of X is low. erefore, we decide not to regularize β at all by simply se ing λ 1 = 0 to decrease the complexity of the design choice space. Nonetheless, we still use glmnet to solve the resultant standard weighted least squares problem due to its matrix-vector friendly interface and high e ciency. We choose λ 2 ∈ {0.1, 0.5, 1, 2, 4, 8}, and λ 3 ∈ 0, 10 −3 , 10 −2 , 10 −1 , 1, 10 . Note that to avoid overparameterization λ 2 cannot be too small. Andnally, we also vary the two parameter tying strategies in Section 2.3.
e selection of λ 2 , λ 3 , and parameter tying strategies, along with the nine cohort design choices in Section 4.3, result in 648 di erent experimental con gurations. Since there are nine di erent types of conditions, the number of BR models that are evaluated in our experiments is 648 × 9 = 5832.
MSCCS Algorithmic Design
An MSCCS model is an equivalent compact representation of a xed e ect Poisson regression model [34] . We therefore are able to use glmnet as a solver for MSCCS by learning the corresponding xed e ect Poisson regression model directly. MSCCS is a model that is only related to β, upon which we impose a ridge penalty in our experiments. Since both BR and MSCCS share the same cohort design choices, to generate 648 experimental con gurations for MSCCS as well, we use a list of 72 tuning parameters for the ridge penalty by ranging the lambda option in the glmnet function in R from 10 −10 to 10 evenly in logarithmic scale. MSCCS without a ridge penalty is also considered. We also apply MSCCS on each of the nine di erent conditions, resulting in a total of 5832 di erent MSCCS models.
Metrics
For each of the 5832 models from both methods (BR and MSCCS), we rank the drugs in ascending order of the corresponding coe cients in the learned β. For each of the two methods, among the models that have the same experimental con gurations, we compute the area under curve (AUC) of receiver operating characteristics (ROC) using the OMOP ground truth and the rankings generated in the previous step. In this way, for both BR and MSCCS, we have 648 AUCs, each for one of the experimental con gurations.
Results of Overall Performance
Since the deployed methods for ADE discovery from LODs usually reported their performances on all experimental con gurations [ 12, 16, [21] [22] [23] [24] 30] , following this protocol, we also analyze the performances of BR and MSCCS under all of our experimental con gurations. Figure 2 visualizes the distributions of AUCs of BR and MSCCS across all 648 experimental con gurations.
e histogram and the box in brown represent the AUC distribution of BR and the cyan ones represent MSCCS. Compared with the AUC distribution of MSCCS, the AUC distribution of BR shi s signi cantly towards higher AUC intervals, with most experimental con gurations achieving AUCs of more than 0.6. On the other hand, most of the experimental con gurations for MSCCS achieve AUCs only between 0.5 and 0.6, which is an indication that most experimental con gurations of MSCCS lack the discriminative power to separate the positive cases from the negative controls. e comparison of the overall performances between the two methods suggests that exploiting the time-varying nature of EHR data can potentially help to more accurately quantify the e ects of drugs on the occurrence rate of adverse events.
Results of Various Cohort Design Choices
e high-variance AUC distributions of BR and MSCCS in Figure 2 motivate us to investigate under what circumstances a model will have be er performance than the other. Notice that both methods share the same cohort design choices as described in Section 4.3; we therefore would like to see the e ect of various cohort design choices on the performance of the two methods. To this end, for each of the 648 di erent BR models, we compute the di erence of AUCs between the BR model and the MSCCS model that has the median AUC among the MSCCS models with the same cohort design choice as the BR model under consideration. We judge that the BR model outperforms the median MSCCS model with the same cohort design choice if the aforementioned di erence of AUCs is larger than zero. Figure 3 visualizes the proportion of BR models that outperform their median MSCCS counterparts with the same cohort design choices. e contrast visualized as bars in di erent colors is distinctive among the proportions of be er-performing BR models with di erent risk window design choices.
Risk Window
When using no risk window at all (none) or a one-month risk window (one month), the majority of BR models outperform their median MSCCS counterparts, in spite of other diversi ed experimental con gurations that have been considered in our experiments.
e proportion of be er performing models under these two risk window design choices range from over 80% to an impressive 90%. As a comparison, for each cohort design choice, exactly half of the MSCCS models will outperform the corresponding median MSCCS model. Furthermore, even compared with the best performer of MSCCS models with a risk window design of none or one month, at least half of the BR models with the same risk window design choices will have be er performance.
On the other hand, when the lasting risk window design choice (lasting) is adopted, it is more challenging for BR models to out perform their median MSCCS counterparts. A possible explanation for this phenomenon is that using a lasting risk window results in fewer and less time-varying intervals within a patient. In this se ing, the data are inherently less time-varying and lack the timedependent information that can be captured and leveraged by a BR model. erefore, a simpler model like MSCCS might be more favorable compared to BR which might run the risk of over ing the baseline if not regularized properly. Furthermore, recall that in our experiments we also use a ridge penalty to regularize the drug e ects β in MSCCS models, while in BR models we do not impose any regularization over β. e lack of time-varying intervals and the lack of regularization upon drug e ects for BR models in this scenario might lead to its suboptimal performance.
Nonetheless, when being properly regularized, BR could still deliver performance comparable to MSCCS when the lasting risk window design is in use. For example, the top performer of BR with lasting risk window gives an AUC of 0.755. In this model, the baseline is heavily regularized by λ 2 = 4 to reduce perturbational time-variability. In comparison, the best performing MSCCS model yields an AUC of 0.763. (Figure 4a ), which is consistent with the top performer reported in the literature [30] . However, assuming every drug having a lasting risk window might lead to potential model misspeci cation because ADEs can be caused by either long-term or short-term drug exposures [25] , and many ADEs in the OMOP ground truth set are in fact acute. On the other hand, using a non-lasting (none or one month) risk window design might be more appropriate for the ground truth set in question. As shown in Figure 4b , when using BR, the ADE signals can still be e ectively detected under non-lasting risk window designs.
Minimum Duration
In Figure 3 , the proportions of be er-performing BR models using various minimum duration design choices are represented in di erent groups. Given a xed risk window, the proportions generated by the three di erent minimum duration thresholds do not vary as signi cantly as using di erent risk window choices. Figure 5 illustrates the e ects of the two parameter tying strategies presented in Section 2.3 on the performance of various BR models. e distribution generated by occurrence tying lies in a range with higher AUCs compared with the distribution generated by interval tying. is phenomenon might be related to the clinical belief that baseline recurrence rates of adverse events tend to be di erent from the rst occurrence rate. While occurrence tying o ers a principal way to quantify this type of prior belief, interval tying might introduce redundant exibility that focuses on perturbational baseline di erence between every adjacent pair of intervals, resulting in the potential tendency to over t the data.
Results of Parameter Tying

Model Selection and Generalization
To demonstrate how well BR can predict unseen adverse events, for a given cohort design choice, we perform Leave-One-ConditionOut-Cross-validation (LOCOCV): for each of the nine conditions, we jointly and adaptively pick λ 2 , λ 3 , and the tying strategy that perform the best on the other eight conditions. In this way, we are able to use the top performer on the known ground truth to predict the unknown. We nd LOCOCV to be a reasonable model selection strategy because, in essence, BR transforms the unsupervised learning of ADEs into a supervised learning problem. During learning, none of the ground truth label information is used. In this scenario, using LOCOCV helps us to maximize the number of training instances that can be used without worrying about the over ing issues introduced by the ADE label information.
e AUCs of the nine di erent cohort design choices generated by LOCOCV are given in Figure 6 . Other than under the lasting risk window, the AUCs of LOCOCV under other con gurations exceed 0.7. In comparison, the best LOCOCV AUC from MSCCS is less than 0.7, which occurs when using a lasting risk window. Other con gurations of MSCCS provide AUCs of around 0.5.
e reasons why we are commi ed to various cohort design choices are that both BR and MSCCS share the same set of cohort design choices, and that given a cohort design, the data (i.e., X, l, and n) used by the two methods are exactly the same, and hence a fair comparison between the two methods can be achieved. Furthermore, in a practical se ing, commi ing to a particular design choice can also help to facilitate the comparison of performances among multiple data sources [27] .
Best Performers
In the literature of ADE discovery from LODs, it is customary to report the best performer of a method learned from a data source [12, 16, [22] [23] [24] 30] . erefore, we also report our top performers of BR and MSCCS in our experiments: the best BR model reaches an AUC of 0.814, with a none risk window, a six months minimum duration threshold, using occurrence tying, λ 2 = 0.5, and λ 3 = 0.1. Note that some of these con gurations are somewhat di erent from the best con gurations reported in Section 4.8, which are determined based on how well a BR model outperforms its best SCCS counterpart with the same cohort design choices rather than based on the absolute AUC value. e best performer of MSCCS reaches an AUC of 0.763, with a lasting risk window, a three months minimum duration threshold, and lambda≈2.5e-3.
DISCUSSION
We have proposed baseline regularization for ADE discovery from LODs. We provide an e ective algorithm from the proximal Newton framework for solving the BR model and compare the performance of BR with MSCCS in a set of diverse experimental con gurations. Future research directions include running BR on other LODs for reproducibility, and accelerating the algorithm by incorporating stochasticity [15, 33, 35] and parallelism [33] . Furthermore, the current experimental con gurations of BR do not consider imposing regularization upon the drug e ects. Based on the performance gain introduced by regularizing the drug e ects in MSCCS models, we speculate that introducing regularization over the drug e ects in BR models will further improve its performance.
